

**AMENDED CLAIMS**

**[Received by the International Bureau on 23 September 2004 (23.09.2004):  
original claims 1 - 8 replaced by amended claims 1-28 (4 pages)]**

1. A method for treating cognitive impairment, the method comprising a step of:  
5 providing to a patient in need thereof an amount of one or more selective dopamine D1-like receptor agonists effective for treating the cognitive impairment using a dosing regimen that minimizes side effects and/or desensitization or tolerance to the treatment and/or provides for long term improvement in cognitive function and/or prevention of further deterioration of cognitive function.
- 10 2. The method of Claim 1, further comprising a step of:  
improving other symptoms related to an underlying disease or cause of the cognitive impairment.
- 15 3. The method of Claim 1, further comprising a step of:  
combining the selective dopamine D1-like receptor agonist with a second drug having some efficacy for treating an underlying disease or cause of the cognitive impairment.
- 20 4. The method of Claim 3, wherein the second drug is a selective dopamine D2 receptor agonist.
5. The method of Claim 4, wherein the selective dopamine D2 receptor agonist is haloperidol.
- 25 6. The method of Claim 3, wherein the combination of the selective dopamine D1-like receptor agonist and the second drug acts additively or synergistically.
7. The method of Claim 1, wherein the selective dopamine D1-like receptor agonist is  
30 DAS-431.
8. A method for generating a profile for correlating dopaminergic state to cognitive impairment, the method comprising steps of:

- determining a dopaminergic status and/or cognitive function of both individual  
35 patients with cognitive impairment and of a population of patients with cognitive  
impairment associated with a particular disease state or normal aging process; and  
correlating the dopaminergic status and/or the cognitive function both in the  
individual patient and in the particular population of patients.
- 40 9. (new) Use of one or more selective dopamine D1-like receptor agonist for the  
preparation of a pharmaceutical pack or kit for the treatment of cognitive impairment.
10. (new) Use of one or more selective dopamine D1-like receptor agonist and a  
selective dopamine D2 receptor agonist for the preparation of a pharmaceutical pack or kit  
45 for the treatment of cognitive impairment.
11. (new) The use according to Claim 9 or Claim 10, wherein said dopamine D1-like  
receptor agonist comprises DAS-431.
- 50 12. (new) The use according to Claim 10 or Claim 11, wherein said selective dopamine  
D2 receptor agonist comprises haloperidol.
13. (new) A pharmaceutical pack or kit for the treatment of cognitive impairment  
comprising one or more selective dopamine D1-like receptor agonist  
55
14. (new) A pharmaceutical pack or kit for the treatment of cognitive impairment  
comprising one or more selective dopamine D1-like receptor agonist and a selective  
dopamine D2 receptor agonist.
- 60 15. (new) The pharmaceutical pack or kit according to Claim 13 or Claim 14, wherein  
said dopamine D1-like receptor agonist comprises DAS-431.
16. (new) The pharmaceutical pack or kit according to Claim 14 or Claim 15, wherein  
said selective dopamine D2 receptor agonist comprises haloperidol.

17. (new) A composition comprising one or more selective dopamine D1-like receptor agonist and a pharmaceutically acceptable carrier or excipient for use as medicament for the treatment of cognitive impairment.
- 70 18. (new) A composition comprising one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist in a pharmaceutically acceptable carrier or excipient for use as medicament for the treatment of cognitive impairment.
- 75 19. (new) The composition according to Claim 17 or Claim 18, wherein said selective dopamine D1-like receptor agonist comprises DAS-431.
20. (new) The composition according to Claim 18 or Claim 19, wherein said selective dopamine D2 receptor agonist comprises haloperidol.
- 80 21. (new) Use of one or more selective dopamine D1-like receptor agonist for the preparation of a medicament for the treatment of cognitive impairment.
22. (new) Use of one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist for the preparation of a medicament for the treatment of cognitive impairment.
- 85 23. (new) The use according to Claim 21 or Claim 22, wherein said dopamine D1-like receptor agonist comprises DAS-431.
- 90 24. (new) The use according to Claim 22 or Claim 23, wherein said selective dopamine D2 receptor agonist comprises haloperidol.
25. (new) The use according to Claim 21, wherein the medicament comprises one or more selective dopamine D1-like receptor agonist receptor ligand and a pharmaceutically acceptable carrier or excipient.
- 95

26. (new) The use according to Claim 22, wherein the medicament comprises one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist and a pharmaceutically acceptable carrier or excipient.

100 27. (new) The use according to Claim 25 or Claim 26, wherein said dopamine D1-like receptor agonist comprises DAS-431.

28. (new) The use according to Claim 26 or Claim 27, wherein said selective dopamine D2 receptor agonist comprises haloperidol.

105

**STATEMENT UNDER**  
**ARTICLE 19(1)**

The claims have been amended to add European format claims. The amended claims find support in the description and drawings as filed and do not introduce any new matter.